Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including ...
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.
The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...
Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...
The US will slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted ...
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
We examine trademark litigation data to reveal how rival drugmakers Novo Nordisk and Eli Lilly are aggressively enforcing ...
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback